837-12-7

Basic information

• Product Name: 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine
• Synonyms: 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine
• CAS NO: 837-12-7
• Molecular Formula: C₁₁H₁₅BrN₂O₂S
• Molecular Weight: 319.23
• Product Categories: alkyl bromide
• Mol File: 837-12-7.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine(837-12-7)
• EPA Substance Registry System: 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine(837-12-7)

Safety Data

• Hazardous Substances Data: 837-12-7(Hazardous Substances Data)

Usage

General Description

1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine is a chemical compound that belongs to the class of piperazine derivatives. It is composed of a piperazine ring with a sulfonyl group and a bromophenyl group attached to it. This chemical has been studied for its potential use as an antipsychotic agent and as a modulator of neurotransmitter systems. It has also been investigated for its potential antimicrobial and antibiofilm activities. Additionally, research has shown that this compound exhibits inhibitory effects on certain enzymes and is being explored for potential therapeutic applications in various diseases and conditions.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 98-58-8 4-bromobenzenesulfonyl chloride 

Downstream Products

• 486422-11-1 4-[(4-methylpiperazin-1-yl)sulfonyl]phenylboronic acid 
• 712268-49-0 N-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-N'-phenyl-4,4'-bipyridine-2,2'-diamine 
• 914610-39-2 1-methyl-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)sulfonyl)piperazine 
• 910903-94-5 [4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-(5-nitro-pyrimidin-2-yl)-amine 
• 486423-57-8 4-amino-4'-[(4-methylpiperazin-1-yl)sulfonyl]-N-pyridin-3-yl-1,1'-biphenyl-3-carboxamide 
• 714237-16-8 3-amino-N-(2-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride 
• 714237-17-9 3-amino-N-(4-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride 
• 714237-32-8 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride 
• 714218-76-5 3-amino-N-(2-methoxyethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride 
• 714218-77-6 3-amino-N-(3-methoxypropyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride 
• 486424-20-8 AZD₂₈₅₈ 

Relevant articles and documents

Illuminating a Dark Kinase: Structure-Guided Design, Synthesis, and Evaluation of a Potent Nek1 Inhibitor and Its Effects on the Embryonic Zebrafish Pronephros

NIMA-related kinase 1 (Nek1) has lately garnered attention for its widespread function in ciliogenesis, apoptosis, and the DNA-damage response. Despite its involvement in various diseases and its potential as a cancer drug target, no directed medicinal chemistry efforts toward inhibitors against this dark kinase are published. Here, we report the structure-guided design of a potent small-molecule Nek1 inhibitor, starting from a scaffold identified by kinase cross-screening analysis. Seven lead compounds were identified in silico and evaluated for their inhibitory activity. The top compound, 10f, was further profiled for efficacy, toxicity, and bioavailability in a zebrafish polycystic kidney disease model. Administration of 10f caused the expansion of fluorescence-labeled proximal convoluted tubules, supporting our hypothesis that Nek1-inhibition causes cystic kidneys in zebrafish embryos. Compound 10f displayed insignificant inhibition in 48 of 50 kinases in a selectivity test panel. The findings provide a powerful tool to further elucidate the function and pharmacology of this neglected kinase.

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.